Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.69 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.69 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | CASP3 | P42574 | 7/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | CASP7 | P55210 | 1/20 | 0.59 |
| ▸ | CASP9 | P55211 | 1/20 | 0.59 |
| ▸ | TGM2 | P21980 | 5/20 | 0.55 |
| ▸ | CES1 | P23141 | 3/20 | 0.55 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7085288 | 0.98 | CA12 (0.67) | CA12CA1CA2CA9CASP3 | |
| Potassium Ion SCHEMBL5858452 | 0.96 | CA12 (0.69) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL40486 | 0.85 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29352151 | 0.85 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL118376 | 0.85 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL20775438 | 0.84 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL2260735 | 0.81 | CA1 (1.00) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL565240 | 0.81 | CA12 (0.69) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL458636 | 0.81 | CA12 (0.69) | CA12CA1CA2CA9CASP3 | |
| SCHEMBL30555218 | 0.81 | CA12 (0.69) | CA12CA1CA2CA9CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12269954-B2 | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) | PROVEPHARM LIFE SOLUTIONS S.A. (FR) | 2025-04-08 | — | — | US | disclosed |
| US-20240076499-A1 | PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | PROVEPHARM LIFE SOLUTIONS S.A. (FR) | 2024-03-07 | — | — | US | disclosed |
| US-11845867-B2 | Process for the preparation of indigotindisulfonate sodium (indigo carmine) | PROVEPHARM LIFE SOLUTIONS S.A. (FR) | 2023-12-19 | — | — | US | disclosed |
| US-20230093526-A1 | PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | PROVEPHARM LIFE SOLUTIONS S.A. (FR) | 2023-03-23 | — | — | US | disclosed |
| US-11499050-B2 | Process for the preparation of indigotindisulfonate sodium (indigo carmine) | PROVEPHARM LIFE SOLUTIONS S.A. (FR) | 2022-11-15 | — | — | US | disclosed |
| US-20210206978-A1 | PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | PROVEPHARM LIFE SOLUTIONS S.A. (FR) | 2021-07-08 | — | — | US | disclosed |
| US-10927258-B2 | Process for the preparation of Indigotindisulfonate sodium (indigo carmine) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2021-02-23 | — | — | US | disclosed |
| EP-3559121-A1 | NOVEL PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | Biophore India Pharmaceuticals Pvt. Ltd. (IN) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018116325-A1 | NOVEL PROCESS FOR THE PREPARATION OF INDIGOTINDISULFONATE SODIUM (INDIGO CARMINE) | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2018-06-28 | — | — | WO | disclosed |
| US-8987474-B2 | Inhibition of Shp2/PTPN11 protein tyrosine phosphatase by NSC-87877, NSC-117199 and their analogs | UNIVERSITY OF SOUTH FLORIDA (US) | 2015-03-24 | — | — | US | disclosed |
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009102433-A2 | COMPOUNDS WITH MDR1-INVERSE ACTIVITY | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | UNIVERSITY OF SOUTH FLORIDA (US) | 2008-07-24 | — | — | US | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| WO-2007117699-A2 | INHIBITION OF SHP2/PTPN11 PROTEIN TYROSINE PHOSPHATASE BY NSC-87877, NSC-117199 AND THEIR ANALOGS | UNIVERSITY OF SOUTH FLORIDA (US) | 2007-10-18 | — | — | WO | disclosed |
| US-6902861-B2 | Infrared absorbing compounds and their use in photoimageable elements | KODAK POLYCHROME GRAPHICS, LLC (US) | 2005-06-07 | — | — | US | disclosed |
| US-20040180285-A1 | Infra red absorbing compounds and their use in photoimageable elements | LASER PACIFIC MEDIA CORPORATION | 2004-09-16 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176309-A1 | 8-hydroxy-7-(6-sulfonaphthalen-2-yl)diazenyl-quinoline-5-sulfonic acid (NSC-87877); Src homology-2 domains; Noonan syndrome, cancer | PTPN7, PTPN1, PTPN2 | CA12 4218/4885CA1 4364/4885CA2 3177/4885 |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | CA12 3730/4885CA1 4063/4885CA2 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.